BAM
CRL icon

Berkshire Asset Management’s Charles River Laboratories CRL Stock Holding History

Berkshire Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,102
Closed -$236K – 221
2022
Q2 		$236K Sell
1,102
-199
-15% -$48.6K 0.02% 205
2022
Q1 		$369K Buy
1,301
+531
+69% +$164K 0.02% 154
2021
Q4 		$290K Buy
+770
New +$299K 0.02% 203

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Berkshire Asset Management's CRL Position: Q3 2022 in Review

Berkshire Asset Management sold out of Charles River Laboratories (CRL) in Q3 2022, closing a stake of 1,102 shares — an estimated $236K sold.

Berkshire Asset Management first reported a position in CRL in Q4 2021 and held it in 3 quarters. The position peaked at $369K in Q1 2022. 583 funds tracked by Wall St. Rank hold CRL as of Q3 2022.

  • Berkshire Asset Management reported no remaining Charles River Laboratories position as of Q3 2022 after selling out during the quarter.
  • Berkshire Asset Management sold 1,102 Charles River Laboratories shares in Q3 2022, an estimated $236K.
  • Berkshire Asset Management first reported a position in Charles River Laboratories in Q4 2021 and held it in 3 quarters.
  • Berkshire Asset Management's Charles River Laboratories position peaked at $369K in Q1 2022.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2022.

Based on Berkshire Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.